Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors.

NCT06191796 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT06191796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06191796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors.
Lead sponsor
Exelixis
Phase
Phase 1
Overall status
Terminated
Start date
January 25, 2024
Completion date
May 12, 2025
Enrollment
25 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced clear cell renal cell carcinoma or other advanced solid tumors